-
Uncategorized1 month ago
Gene Syntax Determines DNA Supercoiling and Modulates Gene Expression
When synthetic biologists sketch gene circuits, they usually think in terms of promoters, repressors, and transcription factors—biochemical parts that toggle genes on or off. But DNA...
-
Uncategorized1 month agoBlood Stem Cells Evade Immune Attack in Aplastic Anemia Through Gene Mutations
Scientists headed by a team at St. Jude Children’s Research Hospital have found that in individuals with the life-threatening blood disorder aplastic anemia (AA), different blood...
-
Uncategorized1 month agoProtein Biomarkers in Practice: Strategies to Reduce Drug Development Risk
Read Now Drug development demands scientific rigor, sustained investment, and confident decision-making under uncertainty. As programs move from early discovery into clinical development, teams must balance...
-
Uncategorized1 month ago
TRACS Enables Strain-Level Tracking of Microbial Transmission
Tracking microbes is challenging, particularly when there are coexisting strains of the same species within metagenomic data. However, overcoming that challenge is important for inferring transmission...
-
Uncategorized1 month agoSTAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
As competition mounts in the red-hot market for weight loss drugs, France’s medicines regulator fined Novo Nordisk approximately $2 million for running “misleading” advertisements for its...
-
Uncategorized1 month agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
Register Now Tilmann Buerckstuemmer, PhD CSOMyllia Biotechnology View Bio Panelist Tilmann Buerckstuemmer, PhD Tilmann Buerckstuemmer, PhD, is a CRISPR enthusiast since the early days of CRISPR....
-
Uncategorized1 month agoOpinion: Mifepristone court ruling makes drug development riskier for everyone
The biotech industry has long operated on a simple premise: FDA-regulated, evidence-based science determines how medicines reach patients, not litigation. That premise was already tested in...
-
Uncategorized1 month ago
FDA search for new CBER head focused on small group of final candidates
The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three to four final candidates, according to...
-
Uncategorized1 month agoCelcuity strengthens case for ASCO-spotlighted breast cancer drug
The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest...
-
Uncategorized1 month ago
Passage cuts 75% of workforce after FDA trial design request
Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include frontotemporal dementia, is exploring strategic alternatives in addition to...
